Skip to main content

Advertisement

SpringerLink
Log in

Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

After approval of the use of ustekinumab for treatment of moderate to severe psoriasis, patients with psoriatic arthritis have treated with this drug in daily clinical practice. The aims of this study were to describe baseline characteristics and evolution of a cohort of patients with psoriasis and psoriatic arthritis treated with ustekinumab and to compare differences between patients who discontinued treatment and those who maintained. A retrospective multicenter observational study including patients who had received ustekinumab for a minimum of 3 months from 2009 to 2015 was performed. The baseline characteristics of the cohort of patients, the main indication for treatment, number and percentage of patients who maintained and discontinued treatment, reasons for discontinuation and differences between patients who discontinued and maintained ustekinumab were evaluated. Fifty-eight patients were included. The main indication was dermatological (72.4% of cases), and treatment with ustekinumab was maintained in most patients (62.1% of cases) with low discontinuation by side effects and rheumatological lack of efficacy. Discontinuation of ustekinumab was correlated with more number of obese patients, less presence of plaque psoriasis and more number of previous biological therapies. Ustekinumab demonstrated efficacy and safety in the management of patients with psoriasis and psoriatic arthritis in daily clinical practice in our cohort of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McInnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780–789

    Article  CAS  PubMed  Google Scholar 

  2. Ritchlin C, Rahman P, Kavanaugh A et al (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73:990–999

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674

    Article  CAS  PubMed  Google Scholar 

  4. Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675–1684

    Article  CAS  PubMed  Google Scholar 

  5. Ibrahim G, Waxman R, Helliwell PS (2009) The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 61:1373–1378

    Article  CAS  PubMed  Google Scholar 

  6. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673

    Article  PubMed  Google Scholar 

  7. Papp K, Gottlieb AB, Naldi L et al (2015) Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14:706–714

    CAS  PubMed  Google Scholar 

  8. Warren RB, Smith CH, Yiu ZZ et al (2015) Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 135:2632–2640

    Article  CAS  PubMed  Google Scholar 

  9. García-Doval I, Pérez-Zafrilla B, Ferrandiz C et al (2016) Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. J Dermatolog Treat 27:203–209

    Article  PubMed  Google Scholar 

  10. Glintborg B, Ostergaard M, Krogh NS et al (2013) Clinical response, drug survival, and predictors there of among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65:1213–1223

    Article  CAS  PubMed  Google Scholar 

  11. Ungprasert P, Thongprayoon C, Davis JM 3rd (2016) Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis. Semin Arthritis Rheum 45:428–438

    Article  CAS  PubMed  Google Scholar 

  12. Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin K (2015) Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients. Br J Dermatol 173:272–274

    Article  CAS  PubMed  Google Scholar 

  13. Di Lernia V, Tasin L, Pellicano R, Zumiani G, Albertini G (2012) Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat 23:404–409

    Article  CAS  PubMed  Google Scholar 

  14. Carrascosa JM, Vilavella M, Garcia-Doval I et al (2014) Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 28:907–914

    Article  CAS  PubMed  Google Scholar 

  15. Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD (2015) Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open 1:e000181

    Article  PubMed  PubMed Central  Google Scholar 

  16. Coates LC, FitzGerald O, Mease PJ et al (2014) Development of a disease activity and responder index for psoriatic arthritis—report of the Psoriatic Arthritis Module at OMERACT 11. J Rheumatol 41:782–791

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Parc de Salut Mar, Barcelona, Spain

    Miriam Almirall

  2. Department of Rheumatology, Hospital de Bellvitge, Hospitalet de Llobregat, Spain

    Jesús Rodriguez

  3. Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain

    Lourdes Mateo

  4. Department of Dermatology, Hospital Germans Trias i Pujol, Badalona, Spain

    José Manuel Carrascosa

  5. Department of Dermatology, Hospital de Bellvitge, Hospitalet de Llobregat, Spain

    Jaime Notario

  6. Department of Dermatology, Parc de Salut Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain

    Fernando Gallardo

Authors
  1. Miriam Almirall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesús Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lourdes Mateo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José Manuel Carrascosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jaime Notario
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fernando Gallardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando Gallardo.

Ethics declarations

The study was approved by the local ethics committee. All patients were required to sign an informed consent.

Disclosures

None.

Additional information

I certify that all authors approve the entirety of the submitted material and contributed actively to the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almirall, M., Rodriguez, J., Mateo, L. et al. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. Clin Rheumatol 36, 439–443 (2017). https://doi.org/10.1007/s10067-016-3464-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-016-3464-x

Keywords

Search

Navigation